Development of FAcE (Formulated Alhydrogel competitive ELISA) method for direct quantification of OAg present in Shigella sonnei GMMA-based vaccine and its optimization using Design of Experiments approach.

J Immunol Methods 2019 08 27;471:11-17. Epub 2019 Apr 27.

GSK Vaccines Institute for Global Health (GVGH) S.r.l., Siena, Italy. Electronic address:

Many formulated vaccines, including 1790GAHB Shigella sonnei GMMA-based vaccine, contain Alhydrogel (aluminum hydroxide), consequently the antigen content must be determined in the formulated final vaccine product, as required by regulatory authorities. The direct quantification of antigens adsorbed on aluminum salts is difficult, and antigens may need to be extracted using laborious and often ineffective desorption procedures. To directly quantify the sugar vaccine target in the LPS of 1790GAHB, we have developed a new FAcE (Formulated Alhydrogel competitive ELISA) method. FAcE is an immunoassay based on the competition between S. sonnei LPS, coated on the ELISA plate, and the LPS in formulated S. sonnei GMMA, in binding a specific monoclonal antibody. To optimize the method, which is as easy to perform as a standard ELISA, we have applied a Design of Experiments (DOE) approach. A model was found to define the significant assay variables and to predict their impact on the output responses. Results obtained using the DOE optimized FAcE assay showed that the method is sensitive (0.02 μg/mL lower detection limit), precise, reproducible and can accurately quantify independently formulated drug products, making it a useful tool in routine tests of Alhydrogel-based vaccines. We are currently using this method to determine S. sonnei vaccine potency, stability and lot-to-lot variations, and are broadening its applicability to quantify active ingredients of other Alhydrogel GMMA-vaccines and in multivalent vaccines formulations.

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00221759183029
Publisher Site
http://dx.doi.org/10.1016/j.jim.2019.04.012DOI Listing
August 2019

Publication Analysis

Top Keywords

sonnei gmma-based
8
alhydrogel competitive
8
competitive elisa
8
elisa method
8
gmma-based vaccine
8
direct quantification
8
design experiments
8
shigella sonnei
8
formulated alhydrogel
8
face formulated
8
formulated
6
sonnei
5
vaccine
5
method
5
easy perform
4
method easy
4
optimize method
4
experiments doe
4
perform standard
4
standard elisa
4

Similar Publications

Characterization of Competitive ELISA and Formulated Alhydrogel Competitive ELISA (FAcE) for Direct Quantification of Active Ingredients in GMMA-Based Vaccines.

Methods Protoc 2020 Aug 31;3(3). Epub 2020 Aug 31.

GSK Vaccines Institute for Global Health s.r.l (GVGH), 53100 Siena, Italy.

Generalized modules for membrane antigens (GMMA) represent a technology particularly attractive for designing affordable vaccines against Gram-negative bacteria. We explored such technology for the development of O-antigen-based vaccines against and nontyphoidal . Adsorption of GMMA on Alhydrogel was required for abrogation of pyrogenicity in rabbits, and GMMA on Alhydrogel was well tolerated and immunogenic in humans. Read More

View Article and Full-Text PDF
August 2020

Production of a Shigella sonnei Vaccine Based on Generalized Modules for Membrane Antigens (GMMA), 1790GAHB.

PLoS One 2015 6;10(8):e0134478. Epub 2015 Aug 6.

Sclavo Behring Vaccines Institute for Global Health S.r.l., Siena, Italy.

Recently, we developed a high yield production process for outer membrane particles from genetically modified bacteria, called Generalized Modules of Membrane Antigens (GMMA), and the corresponding simple two step filtration purification, enabling economic manufacture of these particles for use as vaccines. Using a Shigella sonnei strain that was genetically modified to produce penta-acylated lipopolysaccharide (LPS) with reduced endotoxicity and to maintain the virulence plasmid encoding for the immunodominant O antigen component of the LPS, scale up of the process to GMP pilot scale was straightforward and gave high yields of GMMA with required purity and consistent results. GMMA were formulated with Alhydrogel and were highly immunogenic in mice and rabbits. Read More

View Article and Full-Text PDF
May 2016

Safety Profile and Immunologic Responses of a Novel Vaccine Against Shigella sonnei Administered Intramuscularly, Intradermally and Intranasally: Results From Two Parallel Randomized Phase 1 Clinical Studies in Healthy Adult Volunteers in Europe.

EBioMedicine 2017 Aug 15;22:164-172. Epub 2017 Jul 15.

GSK Vaccines Institute for Global Health, Siena, Italy. Electronic address:

Background: Approximately 164,000 deaths yearly are due to shigellosis, primarily in developing countries. Thus, a safe and affordable Shigella vaccine is an important public health priority. The GSK Vaccines Institute for Global Health (GVGH) developed a candidate Shigella sonnei vaccine (1790GAHB) using the Generalized Modules for Membrane Antigens (GMMA) technology. Read More

View Article and Full-Text PDF
August 2017

Monoclonal Antibodies to Shigella Lipopolysaccharide Are Useful for Vaccine Production.

Clin Vaccine Immunol 2016 08 5;23(8):681-8. Epub 2016 Aug 5.

Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama, USA

There is a significant need for an effective multivalent Shigella vaccine that targets the most prevalent serotypes. Most Shigella vaccines under development utilize serotype-specific lipopolysaccharides (LPSs) as a major component based on protection and epidemiological data. As vaccine formulations advance from monovalent to multivalent, assays and reagents need to be developed to accurately and reproducibly quantitate the amount of LPSs from multiple serotypes in the final product. Read More

View Article and Full-Text PDF
August 2016